Dermata Therapeutics to effect 1-for-10 reverse stock split effective August 1, 2025

Dermata Therapeutics, Inc.

Reverse stock split at 1:10 ratio effective 12:01 a.m. ET on August 1, 2025.
Every ten outstanding common shares convert to one share; no fractional shares (cash in lieu).
CUSIP changes to 249845504; trading on Nasdaq on split-adjusted basis expected August 1.
Board authorized split ratio range of 1:2 to 1:30 at July 15 annual meeting; Board selected 1:10.
Outstanding stock options and warrants will be adjusted proportionally.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Dermata Therapeutics, Inc.: Certificate of Amendment filed to effect a one-for-10 reverse stock split of common stock (effective 2025-08-01).

Change: charter amendment
Effective: 2025-08-01

Exact text from the filing

On July 30, 2025, Dermata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on August 1, 2025, a one-for-10 (1:10) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).

View on SEC.gov

Browse all governance changes →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-021501

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.